Advances in Bioresorbable Stents for Treating PAD
Summary: Advances in Bioresorbable Stents for Treating PAD.
(CRT) conference. March, 2025
“Eric Secemsky, MD, MSc, Director of Vascular Intervention “Associate Professor at Harvard Medical School”, highlighted the resurgence of these innovative devices during his presentation at the Cardiovascular Research Technologies(CRT) conference.
Recent advancements in bioresorbable stent technology are showing promise for the treatment of peripheral artery disease (PAD), particularly below-the-knee interventions.
Key Findings:
1. Improved Designs: New bioresorbable stents, like Abbott’s Esprit, have received FDA clearance and show strong clinical performance, with thinner struts and better design for PAD patients. Other companies, such as Reva Medical and R3 Vascular, are also introducing promising innovations, including smaller strut sizes and improved scaffold materials.
2. Innovative Materials: Biotronik is exploring bioresorbable magnesium stents, which dissolve faster than traditional models, offering a new alternative for PAD patients. These stents lose up to 95% of their mass within a year, unlike PLLA-based scaffolds that dissolve over three to four years.
As research continues, bioresorbable stents show significant progress, offering improved outcomes for PAD patients. While current efforts focus on below-the-knee interventions, there is potential for these stents to be used for above-the-knee PAD treatments and even coronary artery disease in the future. However, new technologies, such as drug-coated balloons, may influence their role in the broader interventional cardiology landscape.
